Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Unmet needs in CML

Joaquin Martinez-Lopez • 10 Sep 2021
IMW 2021
Chronic Myeloid Leukemia Leukemia Ponatinib

Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, gives an overview of the unmet needs in the treatment of chronic myeloid leukemia (CML). Dr Martinez-Lopez focuses on two main clinically unmet needs: long-term toxicities and treatment resistance in CML, and explains how future research may address these. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Joaquin Martinez-Lopez, MD, PhD, has received grant support from BMS; and has performed consultancy work for BMS, Janssen, Novartis, GSK, Incyte, Roche and Astellas.

More from Joaquin Martinez-Lopez

1:26
Laboratory techniques used for immune evaluation in multiple myeloma
Joaquin Martinez-Lopez • 25 Aug 2022
1:19
Infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
Joaquin Martinez-Lopez • 25 Aug 2022
1:04
Manufacturing allogeneic CAR-NKs for the treatment of multiple myeloma
Joaquin Martinez-Lopez • 25 Aug 2022
5:53
COVID-19 in myeloma: what have we learnt?
Joaquin Martinez-Lopez • 10 Sep 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals